BR0316771A - Compostos para o tratamento ou a prevenção de infecções por flavivirus, uso de um composto e composição farmacêutica - Google Patents

Compostos para o tratamento ou a prevenção de infecções por flavivirus, uso de um composto e composição farmacêutica

Info

Publication number
BR0316771A
BR0316771A BR0316771-2A BR0316771A BR0316771A BR 0316771 A BR0316771 A BR 0316771A BR 0316771 A BR0316771 A BR 0316771A BR 0316771 A BR0316771 A BR 0316771A
Authority
BR
Brazil
Prior art keywords
prevention
compounds
compound
treatment
pharmaceutical composition
Prior art date
Application number
BR0316771-2A
Other languages
English (en)
Inventor
Laval Chan Chun Kong
Sanjoy Kumar Das
Hghe Nguyen-Ba
Liliane Halab
Bettina Hamelin
Oswy Z Pereira
Carl Poisson
Melanie Proulx
Trumkunta Jagadeeswar Reddy
Ming-Qiang Zhang
Original Assignee
Virochem Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virochem Pharma Inc filed Critical Virochem Pharma Inc
Publication of BR0316771A publication Critical patent/BR0316771A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D333/40—Thiophene-2-carboxylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"COMPOSTOS PARA O TRATAMENTO OU A PREVENçãO DE INFECçõES POR FLAVIVIRUS, USO DE UM COMPOSTO E COMPOSIçãO FARMACêUTICA". A presente invenção refere-se a novos compostos representados pela fórmula (I) ou seus sais farmaceuticamente úteis para o tratamento de infecção viral por flaviridea.
BR0316771-2A 2002-12-10 2003-12-09 Compostos para o tratamento ou a prevenção de infecções por flavivirus, uso de um composto e composição farmacêutica BR0316771A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43196402P 2002-12-10 2002-12-10
PCT/CA2003/001912 WO2004052885A1 (en) 2002-12-10 2003-12-09 Compounds and methods for the treatment or prevention of flavivirus infections

Publications (1)

Publication Number Publication Date
BR0316771A true BR0316771A (pt) 2005-10-25

Family

ID=42828817

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0316771-2A BR0316771A (pt) 2002-12-10 2003-12-09 Compostos para o tratamento ou a prevenção de infecções por flavivirus, uso de um composto e composição farmacêutica

Country Status (10)

Country Link
EP (1) EP1569929B9 (pt)
JP (1) JP4926403B2 (pt)
AT (1) ATE466856T1 (pt)
AU (1) AU2003291885A1 (pt)
BR (1) BR0316771A (pt)
CA (1) CA2508990C (pt)
DK (1) DK1569929T3 (pt)
MX (1) MXPA05006196A (pt)
NZ (1) NZ540799A (pt)
WO (1) WO2004052885A1 (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004061746A1 (de) * 2004-12-22 2006-07-06 Bayer Healthcare Ag Alkinyl-substituierte Thiophene
MX2007014117A (es) 2005-05-13 2008-02-05 Virochem Pharma Inc Compuestos y metodos para el tratamiento o prevencion de infecciones de flavivirus.
US20090136448A1 (en) * 2005-12-22 2009-05-28 John Andrew Corfield Antiviral 2-Carboxy-Thiophene Compounds
WO2008017688A1 (en) * 2006-08-11 2008-02-14 Smithkline Beecham Corporation 2-carboxy thiophene derivatives as anti-viral agents
WO2008043791A2 (en) * 2006-10-13 2008-04-17 Smithkline Beecham Corporation Thiophene derivatives for treating hepatitis c
AP2579A (en) * 2006-11-15 2013-01-29 Virochem Pharma Inc Thiophene analogues for the treatment or prevention of flavivirus infections
AU2008248116A1 (en) 2007-05-04 2008-11-13 Vertex Pharmaceuticals Incorporated Combination therapy for the treatment of HCV infection
GB0712393D0 (en) * 2007-06-26 2007-08-01 Smithkline Beecham Corp Compounds
US9162980B2 (en) 2009-01-09 2015-10-20 Board Of Regents Of The University Of Texas System Anti-depression compounds
CN102405043B (zh) 2009-01-09 2017-08-22 得克萨斯州大学***董事会 前神经原性化合物
US9962368B2 (en) 2009-01-09 2018-05-08 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
US8362277B2 (en) 2009-01-09 2013-01-29 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
UY32793A (es) 2009-07-21 2011-01-31 Gilead Sciences Inc Compuestos inhibidores de los virus flaviviridae, composición farmacéutica que los contiene y sus usos
JP5774008B2 (ja) * 2009-09-09 2015-09-02 ギリアード サイエンシーズ， インコーポレイテッド Ｆｌａｖｉｖｉｒｉｄａｅウイルスの阻害剤
MX2012006026A (es) 2009-11-25 2012-08-15 Vertex Pharma Derivados de acido 5-alquinil-tiofen-2-carboxilico y usos para tratamiento o prevencion de infecciones por flavivirus.
ES2543105T3 (es) * 2010-01-15 2015-08-14 Gilead Sciences, Inc. Inhibidores de virus flaviviridae
WO2011088345A1 (en) 2010-01-15 2011-07-21 Gilead Sciences, Inc. Inhibitors of flaviviridae viruses
WO2012006070A1 (en) * 2010-06-28 2012-01-12 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flavivirus infections
BR112013000414A2 (pt) 2010-07-07 2016-05-17 Univ Texas compostos proneurogênicos
AU2011292040A1 (en) * 2010-08-17 2013-03-07 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of Flaviviridae viral infections
US8771665B2 (en) 2010-12-17 2014-07-08 Cocrystal Discovery, Inc. Inhibitors of hepatitis C virus polymerase
WO2013010112A1 (en) * 2011-07-13 2013-01-17 Gilead Sciences, Inc. Thiophen-2-carboxylic acid derivatives useful as inhibitors of flaviviridae viruses
WO2013016492A1 (en) 2011-07-26 2013-01-31 Vertex Pharmaceuticals Incorporated Thiophene compounds
WO2014055142A1 (en) 2012-06-20 2014-04-10 Cocrystal Discovery, Inc. Inhibitors of hepatitis c virus polymerase
US8841340B2 (en) 2012-08-17 2014-09-23 Gilead Sciences, Inc. Solid forms of an antiviral compound
US8759544B2 (en) 2012-08-17 2014-06-24 Gilead Sciences, Inc. Synthesis of an antiviral compound
US8927741B2 (en) 2012-08-17 2015-01-06 Gilead Sciences, Inc. Synthesis of an antiviral compound
US9701676B2 (en) 2012-08-24 2017-07-11 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
WO2015070237A1 (en) 2013-11-11 2015-05-14 Board Of Regents Of The University Of Texas System Neuroprotective chemicals and methods for identifying and using same
EP3068388A4 (en) 2013-11-11 2017-04-12 Board of Regents of the University of Texas System Neuroprotective compounds and use thereof
TWI731854B (zh) 2015-03-23 2021-07-01 美商共結晶製藥公司 Ｃ型肝炎病毒聚合酶之抑制劑
CA3096916A1 (en) 2018-05-09 2019-11-14 Cocrystal Pharma, Inc. Combination therapy for the treatment of hepatitis c virus

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995005170A1 (en) * 1993-08-13 1995-02-23 Warner-Lambert Company Methods of inhibiting hiv and inhibiting the activation of hiv
US5734081A (en) * 1994-08-05 1998-03-31 Warner-Lambert Company Arylthio compounds
BR0013143A (pt) * 1999-08-12 2002-06-11 Pharmacia Italia Spa Derivados de 3 (5) amino pirazol, processo para sua preparação e uso dos mesmos como agentes antitumorais
EP1381602A1 (en) * 2001-04-19 2004-01-21 Vertex Pharmaceuticals Incorporated Heterocyclyldicarbamides as caspase inhibitors
CA2449999C (en) * 2001-06-11 2012-07-31 Shire Biochem Inc. Compounds and methods for the treatment or prevention of flavivirus infections
CN100509797C (zh) * 2001-06-11 2009-07-08 病毒化学医药公司 用作黄病毒感染抗病毒剂的噻吩衍生物

Also Published As

Publication number Publication date
EP1569929B1 (en) 2010-05-05
NZ540799A (en) 2008-09-26
JP4926403B2 (ja) 2012-05-09
CA2508990C (en) 2013-05-28
AU2003291885A1 (en) 2004-06-30
MXPA05006196A (es) 2006-01-27
WO2004052885A1 (en) 2004-06-24
CA2508990A1 (en) 2004-06-24
EP1569929B9 (en) 2011-09-14
EP1569929A1 (en) 2005-09-07
DK1569929T3 (da) 2010-08-16
JP2006510636A (ja) 2006-03-30
ATE466856T1 (de) 2010-05-15

Similar Documents

Publication Publication Date Title
BR0316771A (pt) Compostos para o tratamento ou a prevenção de infecções por flavivirus, uso de um composto e composição farmacêutica
EA200400022A1 (ru) Соединения и способы лечения или предупреждения инфекций flavivirus
GB0612423D0 (en) Therapeutic agents
DK2314582T3 (da) Heterocykliske forbindelser som antivirusmidler
BR0309581A (pt) Derivados de nucleosìdeo para tratamento de infecção por vìrus de hepatite c
NO20065075L (no) Ikke-nukleosidbaserte revers-transkriptase-inhibitorer.
NO20052130L (no) Sterk inhibitor for HCV-serin-protease
EA200400585A1 (ru) N-замещённые гидроксипиримидинон-карбоксамидные ингибиторы вич интегразы
ATE512976T1 (de) Hemmer des hepatitis-c-virus
MY151199A (en) Substituted diphenyl heterocycles useful for treating hcv infection
HK1112910A1 (en) Compounds and methods for the treatment or prevention of flavivirus infections
DE60214179D1 (de) IMIDAZOi1,2-AöPYRIDIN-DERIVATE ZUR PROPHYLAXE UND BEHANDLUNG VON HERPES-INFEKTIONEN
BR0209468A (pt) Composto ou sais ou solvatos deste farmaceuticamente aceitáveis, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada pelo hppar
BRPI0515896A (pt) composto ou um sal ou éster farmaceuticamente aceitável do mesmo, método para o tratamento ou profilaxia de um hospedeiro infectado com uma infecção por flavivìrus, pestivìrus ou hepacivìrus, e, composição farmacêutica para o tratamento de um hospedeiro infectado com uma infecção por flavivìrus, pestivìrus ou hepacivìrus
AP2003002915A0 (en) HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis.
BR0210667A (pt) Derivados de oxazolidinonas como agentes antibacterianos
BRPI0607214A2 (pt) derivados de 2-(4-cianofenilamino) pirimidina inibidores de hiv
MXPA04006041A (es) Antivirales de piridoquinoxalina.
TW200508218A (en) Inhibitors of papilloma virus
BR0215067A (pt) Piridoquinoxalinas antivirais
BRPI0519752A2 (pt) compostos peptÍdicos
BR0207102A (pt) Forma cristalina, composição farmacêutica, uso de uma forma cristalina, e, método para a prevenção ou o tratamento de doença
WO2002072581A3 (en) Pyrazolopyriadine derivatives
SE0102058D0 (sv) New Salts II
DK1924255T3 (da) Anvendelse af N-(dibenz(B,F)oxepin-10-ylmethyl)-N-methyl-N-prop-2-ynylamin (OMIGAPIL) til profylakse og/eller behandling af muskeldystrofi

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA INT.CL: C07D 409/12, C07D 333/40, C07D 211/00, A61P 31/00

Ipc: C07D 409/12 (2011.01), C07D 333/40 (2011.01), C07D

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2259 DE 22/04/2014.